miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O

References

• GarzonRMarcucciG. Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr Opin Oncol. 2012;24:655–9.
   PubMed Web of Science ®Google Scholar
• OsantoSQinYBuermansHPBerkersJLerutEGoemanJJ. Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS ONE. 2012;7:e38298.
   PubMed Web of Science ®Google Scholar
• RyanJTivnanAFayJBryanKMeehanMCreeveyL. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer. 2012;107:1203.
   Web of Science ®Google Scholar
• ChenJTianWCaiHHeHDengY. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol. 2012;29:2527–34.
   PubMed Web of Science ®Google Scholar
• ReinhardtHCSchumacherB. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet. 2012;28:128–36.
   PubMed Web of Science ®Google Scholar
• SorensenCSSyljuasenRG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 2012;40:477–86.
   PubMed Web of Science ®Google Scholar
• MasakiTShiratoriYRengifoWIgarashiKYamagataMKurokohchiK. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology. 2003;37:534–43.
   PubMed Web of Science ®Google Scholar
• IornsELordCJGrigoriadisAMcDonaldSFenwickKMackayA. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS ONE. 2009;4:e5120.
   PubMed Web of Science ®Google Scholar
• LiJWangYSunYLawrenceTS. Wild-type TP53 inhibits G2-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat Res. 2002;157:322–30.
   PubMed Web of Science ®Google Scholar
• HiraiHAraiTOkadaMNishibataTKobayashiMSakaiN. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther. 2010;9:514–22.
   PubMed Web of Science ®Google Scholar
• MirSEde WittHPKrawczykPMBalajLClaesANiersJM. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 2010;18:244–57.
   PubMed Web of Science ®Google Scholar
• QiJYuJYShcherbataHRMathieuJWangAJSealS. microRNAs regulate human embryonic stem cell division. Cell Cycle. 2009;8:3729–41.
   PubMed Web of Science ®Google Scholar
• ButzHLikoICzirjakSIgazPKhanMMZivkovicV. Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. J Clin Endocrinol Metab. 2010;95:E181–91.
   PubMed Web of Science ®Google Scholar
• YangJHLiJHShaoPZhouHChenYQQuLH. starBase: a database for exploring microRNA–mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res. 2011;39:D202–9.
   PubMed Web of Science ®Google Scholar
• NakadaCMatsuuraKTsukamotoYTanigawaMYoshimotoTNarimatsuT. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol. 2008;216:418–27.
   PubMed Web of Science ®Google Scholar
• WangXLiBWangJLeiJLiuCMaY. Evidence that miR-133a causes recurrent spontaneous abortion by reducing HLA-G expression. Reprod Biomed Online. 2012;25:415–24.
   PubMed Web of Science ®Google Scholar
• KimYJKetterRSteudelWIFeidenW. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol. 2007;128:118–25.
   PubMed Web of Science ®Google Scholar
• RajeshkumarNVde OliveiraEOttenhofNWattersJBrooksDDemuthT. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 2011;17:2799–806.
   PubMed Web of Science ®Google Scholar
• GarimellaSVRoccaALipkowitzS. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Mol Cancer Res. 2012;10:75–85.
   PubMed Web of Science ®Google Scholar
• CozziMGiorgiFMarcelliEPentimalliFForteIMSchenoneS. Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition. Cell Cycle. 2012;11:1029–39.
   PubMed Web of Science ®Google Scholar
• PosthumaDeBoerJWurdingerTGraatHCvan BeusechemVWHelderMNvan RoyenBJ. WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer. 2011;11:156.
   PubMed Web of Science ®Google Scholar
• HiraiHIwasawaYOkadaMAraiTNishibataTKobayashiM. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009;8:2992–3000.
   PubMed Web of Science ®Google Scholar
• LavecchiaAGiovanniCDNovellinoE. CDC25 phosphatase inhibitors: an update. Mini Rev Med Chem. 2012;12:62–73.
   PubMed Web of Science ®Google Scholar
• GruberRZhouZSukchevMJoerssTFrappartPOWangZQ. MCPH1 regulates the neuroprogenitor division mode by coupling the centrosomal cycle with mitotic entry through the Chk1–Cdc25 pathway. Nat Cell Biol. 2011;13:1325–34.
   PubMed Web of Science ®Google Scholar
• KristjansdottirKRudolphJ. Cdc25 phosphatases and cancer. Chem Biol. 2004;11:1043–51.
   PubMed Web of Science ®Google Scholar
• BraultLBagrelD. Activity of novel Cdc25 inhibitors and preliminary evaluation of their potentiation of chemotherapeutic drugs in human breast cancer cells. Life Sci. 2008;82:315–23.
   PubMed Web of Science ®Google Scholar
• KiyokawaHRayD. In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets. Anticancer Agents Med Chem. 2008;8:832–6.
   PubMed Web of Science ®Google Scholar
• de WittHPMirSENoskeDvan NoordenCJWurdingerT. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res. 2011;17:4200–07.
   PubMed Web of Science ®Google Scholar
• BlenkSEngelmannJCPinkertSWenigerMSchultzJRosenwaldA. Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis. BMC Cancer. 2008;8:106.
   PubMedGoogle Scholar
• Kiviharju-afHTJaamaaSMonkkonenMPeltonenKAnderssonLCMedemaRH. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci USA. 2007;104:7211–16.
   PubMed Web of Science ®Google Scholar
• BackertSGelosMKobalzUHanskiMLBohmCMannB. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. Int J Cancer. 1999;82:868–74.
   PubMed Web of Science ®Google Scholar
• YoshidaTTanakaSMogiAShitaraYKuwanoH. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol. 2004;15:252–6.
   PubMed Web of Science ®Google Scholar
• HartmannJTBokemeyerC. Chemotherapy for renal cell carcinoma. Anticancer Res. 1999;19:1541–3.
   PubMed Web of Science ®Google Scholar
• WangYLiJBooherRNKrakerALawrenceTLeopoldWR. Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator. Cancer Res. 2001;61:8211–7.
   PubMed Web of Science ®Google Scholar
• WangYDeckerSJSebolt-LeopoldJ. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther. 2004;3:305–13.
   PubMed Web of Science ®Google Scholar
• GaoSChenTChoiMYLiangYXueJWongYS. Cyanidin reverses cisplatin-induced apoptosis in HK-2 proximal tubular cells through inhibition of ROS-mediated DNA damage and modulation of the ERK and AKT pathways. Cancer Lett. 2013;pii:S0304-3835(13)00079-7.
   Google Scholar
• MurrowLMGarimellaSVJonesTLCaplenNJLipkowitzS. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat. 2010;122:347–57.
   PubMed Web of Science ®Google Scholar